CliniGene - NoE

Involving EC Networks: CliniGene, BetaCellTherapy, Crystal, ESTOOLS, Liv-ES, NeuroStemCell, Optistem & Screentox

Scientific Committee: Peter W. Andrews, Olivier Brüstle, Elena Cattaneo, Odile Cohen-Haguenauer (co-Chair), Jürgen Hescheler, Marc Peschanski (Chair), Daniel Pipeleers, Anne Weber

presented by CliniGene with the participation of EC-DG Research in Health and the European Medicines Agency

Organising Committee: Odile Cohen-Haguenauer (Chair), Fatima Bosch, Manuel Carrondo, Klaus Cichutek, Nicole Deglon, George Dickson, Bernd Gänsbacher, Gösta Gahrton, Christof von Kalle, David Klatzmann, Stefan Kochanek, Seppo Yla-Herttuala

Speakers:

Keynote: Mario Capecchi, Kathy High, Luigi Naldini,Inder Verma.

Alessandro Aiuti, Robin Ali, Nathalie Cartier, Jacqueline Corrigan-Curay,Pedro Cruz, Janneke De Wal, Anne Galy, David Gancberg, Mauro Giacca, Arnd Hoeveler, Nancy King, Lucio Luzzatto, Stéphane Palfi, Marisa Papaluca-Amati, Jude Samulski, Daniel Scherman, Manfred Schmidt, Thierry Vandendriessche, and organising committee.

The NIH RAC and CliniGene to Co-host a Scientific Symposium on "Retroviral and Lentiviral Vectors for Long-Term Gene Correction: Clinical Challenges in Vector and Trial Design" - In past safety symposia, the RAC reviewed clinical and molecular data concerning leukemias caused by insertional mutagenesis at or near oncogenes in two trials for X-linked Severe Combined Immunodeficiency Disease (X-SCID) involving transduction of CD34+ hematopoetic stem cells by retroviral vectors. Since these discussions, investigators have reported advances in the field, including clinical benefits in trials studying other clinical indications (e.g., adenosine deaminase deficient-SCID, adrenoleukodystrophy). In addition, research has focused on alternative vectors, either lentiviral vectors or modified retroviral vectors designed to decrease the risk of enhancer-mediated insertional mutagenesis.   Given these developments, as well as recent reports of myelodysplasia in a trial for chronic granulomatous disease and the finding of a relative clonal population of cells in a trial for thalassemia, the NIH Recombinant DNA Advisory Committee (RAC) and the European Network for the Advancement of Clinical Gene Transfer and Therapy (CliniGene) are holding this symposium to review:  

• Developments in retrovirus and lentivirus integration and insertional mutagenesis research, including non-enhancer mediated mechanisms of insertional mutagenesis;
• Modifications to retroviral and lentiviral vectors to enhance their safety;
• Research on in vitro and animal models to evaluate the safety of human gene transfer; and
• Clinical and ethical considerations for review of human gene transfer research involving novel retroviral and lentiviral vectors.

The symposium will be held December 9-10, 2010 at the Bethesda Marriott, 5151 Pooks Hill Road, Bethesda, MD.  This meeting is open to the public and free of charge.  Participants are not required to preregister.  Seating is available on a first come basis.   For more information, please contact:

• in Europe: CliniGene by email at clinigene.admi@ens-cachan.fr or by telephone at  +33 1-4740-7658 and Fax at +33 1-4740-6883
• in the US: OBA, by email at oba@od.nih.gov or by telephone at +1 301-496-9838

Bottlenecks in the Industrial development of cell and gene-based therapeutics

Monday October 25^th 2010, Milan (Italy) 13:15 – 19:00

In parallel of the ESGCT session CliniGene is organising 3 closed sessions (for CliniGene members only):

• IMPD meeting (Friday 22 from 15:00 to 18:00 or Sunday 24 from 17:00 to 19:00)
• CliniGene closed meeting on Flexifunds with dinner (Friday 22 from 20:00 to 23:00)
• Executive Committee (Saturday 23:00 from 17:00 to 19:00)

The hematopoietic System as tool and target for Gene Therapy

 

Scientific program of high quality concentrates in gene therapy and viral vectors, where the practical course provides hands-on training  of the most widely used viral vectors (upstream and downstream process and in vivo use).

The ESMI succeed in showing the advantage of translational networking by bringing together physicists, technologists, physicians, biologists, and chemists; as well as by the close organisational collaboration with EU funded network-projects "DiMI– Diagnostic Molecular Imaging” as well as “Clinigene – Clinical Gene and Cell Therapy” and the “European Society for Radiology – ESR”. The meeting was also supported through “COST Actions – European Cooperation in Science and Technology”.

CliniGene International Board Meeting

The Thirteenth Annual Meeting & Clinical Trials Training Course of the American Society of Gene & Cell Therapy

Programme and abstracts available only to Clinigene members via Clinisoft